Table 2.
Incidence (per 100 person-years) of new-onset AF in diabetic patients taking metformin plus DPP4i or other hypoglycemic agents
| New-onset AF | |||||
|---|---|---|---|---|---|
| Numbers | Events | Incidence before weighting | Incidence after weighting | HRa
95% CI P value |
|
| DPP4i | 16,017 | 45 | 0.14 (0.10–0.18) | 0.14 (0.12–0.15)* | 1.00 (Reference) |
| Other hypoglycemic agents rather than DPP4i | 74,863 | 386 | 0.21 (0.19–0.24) | 0.21 (0.19–0.23) | 1.53 (1.31–1.78) P < 0.0001 |
| Sulfonylurea | 62,216 | 318 | 0.20 (0.18–0.23) | 0.20 (0.18–0.23) | 1.45 (1.24–1.70) P < 0.0001 |
| Alpha glucosidase inhibitor | 5091 | 24 | 0.24 (0.14–0.33) | 0.23 (0.15–0.32) | 1.75 (1.19–2.57) P = 0.0045 |
| Meglitinide | 5164 | 41 | 0.38 (0.26–0.49) | 0.38 (0.27–0.48) | 2.78 (2.05–3.76) P < 0.0001 |
| TZD | 3091 | 15 | 0.23 (0.11–0.34) | 0.23 (0.12–0.33) | 1.68 (1.05–2.69) P = 0.0307 |
| Insulin | 1361 | 3 | 0.11 (0.02–0.32) | 0.11 (0.03–0.29) | 0.79 (0.28–2.26) P = 0.20 |
| GLP1 | 5 | 0 | |||
There were 2016 patients taking more than two hypoglycemic agents as second-line hypoglycemic agents at the same time
ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, CI confidence interval, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1; PAOD peripheral arterial obstructive disease, TZD thiazolidinedione
aFor other hypoglycemic agents versus DPP-4 inhibitors (reference) after propensity score weighting